Telix Pharmaceuticals Limited (ASX:TLX)

Market Cap	10.15B
Revenue (ttm)	783.21M
Net Income (ttm)	49.92M
Shares Out	336.87M
EPS (ttm)	0.14
PE Ratio	208.30
Forward PE	100.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,203,113
Average Volume	1,190,583
Open	29.01
Previous Close	26.46
Day's Range	28.66 - 30.50
52-Week Range	10.57 - 30.50
Beta	2.41
RSI	67.43
Earnings Date	Feb 19, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TLX

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.